On this page you will find a list of surveys from, or endorsed by, ABS members.

Submit a Survey


If you would like to submit a survey to gain input from the ABS membership please email a link or a list of questions to

All surveys must be from, or endorsed by, an ABS or Mammary Fold member. Approved surveys will also be circulated in the ABS newsletter or monthly bulletin emails.

We are currently looking for sites to participate in this trial. The study schema can be found in the questionnaire. 

If your unit would be interested in participating in this trial then please download the questionnaire here and return to:

Post-operative infection in patients undergoing breast implant surgery can lead to explantation. Whilst current ABS standards are set at <5% implant loss at 3 months, the National Mastectomy and Breast Reconstruction audit showed that 15-18% of women undergoing immediate reconstruction experience serious complications, and iBRA's recent data gathering showed implant loss rates of 8.9%, highlighting the need for improvements in practice. Aseptic technique is paramount in all stages of the operation and Allergan'sTM 14-point plan was developed by Deva and colleagues in an attempt to minimise complications. Moreover, there are associations that the biofilm is involved in the pathogenesis of breast implant associated anaplastic large cell lymphoma (BIA-ALCL), an area of increasing concern, particularly for textured implants. A 17 question online survey was disseminated to 40 breast surgeons in the Kent, Surrey and Sussex Deanery in 2018 and responses analysed in relation to the 14-point plan and the results were presented at the ABS meeting in 2018. This showed variable practice with both reconstructive and augmentation surgery. To further our understanding study we would greatly appreciate your co-operation in filling out the survey in the link below to help us gather data on a national level. This could help introduce a more robust strategy like the WHO safety checklist, and improve current practice to meet ABS standards.

To complete the study please click here


Breast reconstruction is now considered to be one of the pillars of breast cancer treatment. Before the introduction of acellular dermal matrix (ADM) there were limitations to the use of implant based reconstruction to which the ADM provides a solution. The use of ADM has increased the number of a single-stage direct to implant breast reconstructions subsequently reducing the number of two-stage reconstructions. Unfortunately however, there are several complications associated with the use of ADM of which seroma is the most frequent. The term seroma is not well defined in the international literature and it is still debatable if it is related to the use of an ADM, at what point we label it as a seroma and how best to manage it. The aim of this short survey is to help find the answers to those questions in order to better define the concept of seroma related to ADM.

G. Zoccali, N. Seyidova, R. Price, M. Ho-Asjoe.

Plastic Surgery department, Guy’s and St Thomas’ NHS Foundation Trust, London UK 

Click here to complete the survey and contact or 07490216119 with any questions.

ALCL - current Ireland/UK perspective

The purpose of this survey is to determine the current perspective of breast surgeons with regards to ALCL risk and breast implant practice.


Researchers are looking for healthcare professionals involved in the care of patients considering Contralateral Prophylactic Mastectomy (CPM) to take part in a study exploring the decision making process.

This will involve a 10-minute online survey, including questions about the decision making process, treatment pathways and your attitude towards CPM.

To take part, please visit:

If you’d be like to find out more about this research,
please contact Dr Pippa Tollow at the University of the West of England:
0117 32 87389

ATNEC: Axillary management in T1-3N1M0 breast cancer patients with FNA or core biopsy proven nodal metastases at presentation who convert to node negative after NEoadjuvant Chemotherapy

We would like to establish the level of interest in this proposed non-commercial study. Please find attached a trial summary for your information. The proposal is being submitted to NIHR HTA for funding. 

In order to register your interest in this study, we would be very grateful if you could review the trial summary and then complete the online survey at: no later than 15th December 2017

Important note: To aid completion of the survey and prior to entering your answers online, each of the questions may be reviewed in the attached PDF.  Please do not complete the PDF version.  All answers should be entered directly into the online survey. 

If you have any questions please contact Amit Goyal on or 01332 785538.

Find more information here and complete the survey here

Thank you for agreeing to take part in this survey. Following the AXISS (Axillary Survey study) survey on the axillary treatment of SN-positive breast cancer patients, this survey focuses on breast cancer with nodal positivity confirmed at diagnosis (cN+ patients). The aim is to gain information on current practices for axillary staging and management of cN+ patients receiving neoadjuvant chemotherapy (NAC). 
Complete the survey here

A national survey to look into which routine pre-operative staging investigations are performed for primary breast cancer amongst breast surgeons in the UK.
Mr Prakash Sinha, Mr Abdul Kasem, Ms Leyla Swafe, Dr Agatha Koutsouveli
Princess Royal University Hospital – King’s College Hospital NHS Trust

We would be very grateful if you could please fill in the following questionnaire online which should not take more than a 5 minutes:

We are a group of researchers and clinicians from Oxford, Newcastle, London, Swansea, Warwick and Manchester, who are developing an intervention based on behavioural theory, to support women with breast cancer to adhere to a full course of prescribed adjuvant endocrine therapy (AET) in order to minimise their chance of cancer recurrence. We are exploring who may be best to deliver the intervention across the UK. Breast care nurses are the health professionals who we think have the most initial contact with this group of women and may be in a position to deliver this intervention. However, we are aware that there may be other health care professionals who could also take this role.  It is crucial for the success of the intervention that we understand your views on this. We are asking whether you could answer the following short survey.

Objectives of the SWEET study:

  1. To understand current follow up models of care
  2. To understand what kind of advice and support women currently receive around adjuvant endocrine therapy (AET)
  3. To explore potential models of delivery of future intervention to support adherence to endocrine therapy (AET)

 Please click on this link to undertake the survey.  There are 25 questions and we anticipate it should take up to 15 minutes maximum.  Thank you very much for your help.

Thank you to everyone who participated in the iBRA study - the largest prospective study of mesh-assisted implant breast reconstruction worldwide.

iBRA demonstrated huge variation in the practice and outcomes of implant-based breast reconstruction but did not demonstrate any significant differences in outcomes between different techniques with and without mesh.

We are now in the process of designing the iBRA trial and would like your input on what type of trial you feel would be feasible; what the comparators should be and what outcomes we should measure and when.

We would be very grateful if you could complete the brief survey by clicking here

Many thanks in advance

Miss Shelley Potter and Professor Chris Holcombe

On behalf of the iBRA Steering Group

We are designing a robust panel assessment scale for breast reconstruction for use in a multi-centre study.  
Your opinion of the most important domains to include is most appreciated.
Thank you for your time, it will take no longer than 5 minutes.
Find the survey here

Recruitment to clinical trials and research underpins all we do, and is key to the ABS strategy. 

We recognise that this can be challenging and we want to help you support our members with trial recruitment. 

Please help by completing the attached questionnaire and tell us how we can do that. 

Thanks for your help.

Chris Holcombe, Chair of the ABS Academic and Research Committee

Find the survey here

The iBRA-NET study group would like you to let them know about your current practice of breast lesion localisation. They ask that this survey is completed once for each unit. Find the survey here 

Phases two and three of the localisation study will ask for your help in a prospective audit of your current localisation technique and to evaluate the effectiveness of new technologies including Magseed.

iBRA-NET aims to help us all to evaluate new techniques in a safe and reproducible way and to share experiences and learning.